California is currently home to 5930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Optimizing IV Gentamicin in JEB
Recruiting
Herlitz junctional epidermolysis bullosa (H-JEB), an incurable and fatal inherited skin disease, is caused by loss-of-function mutations in LAMA3, LAMB3 and LAMC2. These mutations result in diminished laminin 332 and epidermal-dermal adherence. 85% of JEB patients have nonsense mutations in LAMA3, LAMB3, or LAMC2, suggesting that H-JEB is a prime therapeutic target for nonsense suppression therapy. The investigators recently demonstrated in three patients that topical gentamicin created new and... Read More
Gender:
All
Ages:
30 days and above
Trial Updated:
11/01/2022
Locations: University of Southern California, Los Angeles, California
Conditions: Junctional Epidermolysis Bullosa
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recruiting
Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable, devastating, inherited skin disease caused by mutations in the COL7A1 gene that encodes for type VII collagen (C7), the major component of anchoring fibrils (AFs), structures that mediate epidermal-dermal adherence. Thirty percent of RDEB patients have nonsense mutations. The investigators recently demonstrated in 5 such patients that intradermal and topical gentamicin induced "read-through" of their nonsense mutations and create... Read More
Gender:
All
Ages:
7 years and above
Trial Updated:
11/01/2022
Locations: University of Southern California, Los Angeles, California
Conditions: Recessive Dystrophic Epidermolysis Bullosa
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting
An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.
Gender:
All
Ages:
30 years and above
Trial Updated:
10/31/2022
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California
Conditions: Stroke, TIA, Ischemic Stroke, Ischemic
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Recruiting
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Gender:
All
Ages:
All
Trial Updated:
10/31/2022
Locations: Doheny Eye Center UCLA, Fountain Valley, California
Conditions: Glaucoma, Ocular Surface Disease
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Todd Lanman, MD, Inc., Beverly Hills, California
Conditions: Symptomatic Cervical Disc Disease
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
Recruiting
STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease. Secondary: To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
10/27/2022
Locations: John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California
Conditions: Alzheimer Dementia
Multiomic Diagnostics in Youth With Psychosis
Recruiting
Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identif... Read More
Gender:
All
Ages:
Between 7 years and 17 years
Trial Updated:
10/24/2022
Locations: Rady Children's Hospital San Diego, San Diego, California
Conditions: Psychosis
Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
Recruiting
Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12 week open-label extension to examine the immunomodulatory activity of PTM-001 in participants with Hidradenitis Suppurativa (HS). Participants will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all participants will receive open-label PTM-001 400 mg daily for an additional 12 weeks. Randomization will be stratified by Hurley Stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Phoenicis Investigative Site, Redwood City, California
Conditions: Hidradenitis Suppurativa
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
Recruiting
This study will evaluate two alternative dressings compared to a standard Island dressing presently in use at Stanford Hospital to determine reductions in surgical site infection (SSI) rates among cardiac surgery patients. Cardiovascular surgery patients who will have a sternotomy incision as a routine part of their surgery will be approached to voluntarily participate. Participants will be randomized to one of three dressing to determine which dressing has the lowest rate of sternal wound infec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Stanford Healthcare, Stanford, California
Conditions: Wound of Skin
Establish ProLung Test Measurement Collection Protocol for Future Studies.
Recruiting
The purpose of this Study is to identify and test different data collection methods to determine which approaches improve the ProLung Testing procedure. Once this Study is complete, the Sponsor plans to evaluate these improvements in future follow up Validation studies that will assess device accuracy using the new measurement collection methods.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Coastal Pulmonary Associates, Encinitas, California
Conditions: Cancer , Healthy
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
Recruiting
The purpose of this study is to study the long term safety and effectiveness of an artificial iris prosthesis for the treatment of iris defects.
Gender:
All
Ages:
3 years and above
Trial Updated:
10/21/2022
Locations: Advanced Vision Care, Los Angeles, California
Conditions: Full Aniridia, Partial Aniridia